[{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"117ac5eb-6cd3-4e16-a1da-430f5c6a5c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045571","created_at":"2025-07-05T14:02:04.651Z","updated_at":"2025-07-05T14:02:04.651Z","phase":"","brief_title":"MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer","source_id_and_acronym":"NCT07045571","lead_sponsor":"Yingbin Liu, MD, PhD, FACS","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 01/22/2026","primary_completion_date":" 01/22/2026","study_txt":" Completion: 07/22/2026","study_completion_date":" 07/22/2026","last_update_posted":"2025-07-01"},{"id":"5e80e055-53fb-476a-823d-dd55cbbde48c","acronym":"CLARITI","url":"https://clinicaltrials.gov/study/NCT06947382","created_at":"2025-09-07T01:25:10.607Z","updated_at":"2025-09-07T01:25:10.607Z","phase":"","brief_title":"Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer","source_id_and_acronym":"NCT06947382 - CLARITI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 1066","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 12/09/2024","primary_completion_date":" 12/09/2024","study_txt":" Completion: 01/06/2025","study_completion_date":" 01/06/2025","last_update_posted":"2025-04-27"},{"id":"9a5ed2f1-0ba5-4ea5-9318-4cb37ecaf26a","acronym":"VERIFI","url":"https://clinicaltrials.gov/study/NCT06947395","created_at":"2025-07-19T13:21:57.123Z","updated_at":"2025-07-19T13:21:57.123Z","phase":"","brief_title":"Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)","source_id_and_acronym":"NCT06947395 - VERIFI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 386","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 04/07/2025","study_completion_date":" 04/07/2025","last_update_posted":"2025-04-27"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"40c7efdf-8bc2-49bd-8de1-be213f764540","acronym":"","url":"https://clinicaltrials.gov/study/NCT06825546","created_at":"2025-02-25T15:16:34.142Z","updated_at":"2025-02-25T15:16:34.142Z","phase":"Phase 2","brief_title":"Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06825546","lead_sponsor":"Sir Run Run Shaw Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • icaritin (SNG-162)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"876ce078-02f8-4b29-96fc-e46147d9c92f","acronym":"PYX-201-101","url":"https://clinicaltrials.gov/study/NCT05720117","created_at":"2023-09-21T18:11:07.087Z","updated_at":"2025-02-25T16:39:39.072Z","phase":"Phase 1","brief_title":"Study of PYX-201 in Solid Tumors","source_id_and_acronym":"NCT05720117 - PYX-201-101","lead_sponsor":"Pyxis Oncology, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e micvotabart pelidotin (PYX-201)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-06"},{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"4d499930-5bc3-44f2-ad4f-201e4b3a7fae","acronym":"","url":"https://clinicaltrials.gov/study/NCT06807112","created_at":"2025-02-25T16:57:38.918Z","updated_at":"2025-02-25T16:57:38.918Z","phase":"","brief_title":"The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06807112","lead_sponsor":"Charles University, Czech Republic","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-04"},{"id":"8b58c0df-729c-4290-be19-9352e417c12d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03851237","created_at":"2021-07-05T17:20:30.966Z","updated_at":"2025-02-25T16:52:26.049Z","phase":"Phase 1","brief_title":"CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy","source_id_and_acronym":"NCT03851237","lead_sponsor":"Washington University School of Medicine","biomarkers":" CCR2","pipe":"","alterations":" ","tags":["CCR2"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-04"},{"id":"6bcd23c9-26d4-4ce6-8abc-592de885dbb3","acronym":"TWINPEAK","url":"https://clinicaltrials.gov/study/NCT05482893","created_at":"2022-08-01T14:54:48.052Z","updated_at":"2025-02-25T16:18:00.073Z","phase":"Phase 1/2","brief_title":"Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)","source_id_and_acronym":"NCT05482893 - TWINPEAK","lead_sponsor":"Phanes Therapeutics","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-01-31"},{"id":"d8337ec5-4498-4bd7-8eca-3f7f9310b053","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431270","created_at":"2024-01-29T19:19:52.186Z","updated_at":"2025-02-25T17:25:40.711Z","phase":"Phase 1/2","brief_title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","source_id_and_acronym":"NCT05431270","lead_sponsor":"Phanes Therapeutics","biomarkers":" CD73","pipe":" | ","alterations":" PD-L1 expression","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-01-31"},{"id":"4706d16d-ce42-4f66-bf31-03fdd9664763","acronym":"CENDIFOX","url":"https://clinicaltrials.gov/study/NCT05121038","created_at":"2021-11-16T13:54:02.602Z","updated_at":"2025-02-25T16:26:46.910Z","phase":"Phase 1/2","brief_title":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","source_id_and_acronym":"NCT05121038 - CENDIFOX","lead_sponsor":"Anup Kasi","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-12-17"},{"id":"b2c9ef7d-2fb3-45a4-a86b-257c668139cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03767582","created_at":"2021-02-23T17:53:27.774Z","updated_at":"2025-02-25T14:27:51.862Z","phase":"Phase 1/2","brief_title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","source_id_and_acronym":"NCT03767582","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9","pipe":"","alterations":" ","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-12-10"},{"id":"e92801f2-3769-4416-bd81-1192ec053342","acronym":"","url":"https://clinicaltrials.gov/study/NCT02754726","created_at":"2021-01-18T13:30:16.481Z","updated_at":"2025-02-25T14:36:19.669Z","phase":"Phase 2","brief_title":"Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT02754726","lead_sponsor":"HonorHealth Research Institute","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/11/2023","primary_completion_date":" 04/11/2023","study_txt":" Completion: 03/22/2024","study_completion_date":" 03/22/2024","last_update_posted":"2024-12-10"},{"id":"a4ed02c4-6f06-4ed4-a5b9-d63c7176c2eb","acronym":"LEAP-005","url":"https://clinicaltrials.gov/study/NCT03797326","created_at":"2021-01-17T17:13:36.138Z","updated_at":"2025-02-25T13:35:11.465Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","source_id_and_acronym":"NCT03797326 - LEAP-005","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 603","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 10/28/2024","primary_completion_date":" 10/28/2024","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2024-11-15"},{"id":"9455efaa-e977-4616-8644-72913019ad15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989387","created_at":"2021-08-04T13:52:52.724Z","updated_at":"2025-02-25T16:16:34.090Z","phase":"Phase 1","brief_title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04989387","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-11-06"},{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"5b18e518-5abe-49ce-9ea4-7ddcd3927bd8","acronym":"SPORE","url":"https://clinicaltrials.gov/study/NCT04666740","created_at":"2021-01-19T20:43:48.854Z","updated_at":"2025-02-25T16:10:54.810Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","source_id_and_acronym":"NCT04666740 - SPORE","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-10-14"}]